Back

ENVISAGE-TAVI AF: edoxaban vs. vitamin K antagonists after TAVI in patients with atrial fibrillation

28 August 2021 (14:30 - 14:42)
Organised by:
Congress Presentation Part of: Hot Line - ENVISAGE-TAVI AF Anticoagulants ESC Premium Access ESC Congress 2021 - The Digital Experience

About the speaker

Photo
Professor George Dangas

Mount Sinai Medical Center, New York (United States of America)

2 More presentations in this session

Presentation thumbnail
ENVISAGE-TAVI AF - Discussant review.
Professor J. Collet (Paris, FR)
Slides Video
Presentation thumbnail
ENVISAGE-TAVI AF - Panel discussion.

Access the full session

Session thumbnail
Hot Line - ENVISAGE-TAVI AF
Video

The Event

Event poster

ESC Congress 2021 - The Digital Experience

28 August 2021 14:30 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes in patients receiving oral anticoagulation stratified by the presence of dose reduction criteria and older age: a subanalysis of ENVISAGE-TAVI AF
25 August 2023
thumbnail
Congress Session
ESC Paul Hugenholtz Lecture in Innovation
25 August 2023
thumbnail
Congress Presentation
Atrial fibrillation in transfemoral transcatheter aortic valve implantation
31 August 2025
thumbnail
Congress Presentation
Comparison of clinical outcomes with edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonist in patients with atrial fibrillation in Germany: a real-world cohort study
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources